By Professor Gail Matthews

Journal articles

Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Geskus RB; Dore GJ; Grebely J; Lauer G; Shoukry NH; Hahn J; Shiboski S; Rice TM; Alavi M; Bouchard R; Aneja J; Teutsch S; White B; Wells B; Zang G; Matthews G; Marks P; Yeung B; Prince LE; Roy E; Bates A; Enriquez J; Chow S; McCredie L; Aitken C; Doyle J; Spelman T; Evans J, 2014, 'Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC³ Study', Journal of Clinical Virology, 61, pp. 430 - 434, http://dx.doi.org/10.1016/j.jcv.2014.08.027

Hajarizadeh B; Grebely J; Applegate T; Matthews GV; Amin J; Petoumenos K; Hellard M; Rawlinson W; Lloyd A; Kaldor J; Dore GJ; Dolan K, 2014, 'Dynamics of HCV RNA Levels During Acute Hepatitis C Virus Infection', Journal of Medical Virology, 86, pp. 1722 - 1729, http://dx.doi.org/10.1002/jmv.24010

Martinello M; Chow DH; Danta M; Matthews GV; Dore GJ, 2014, 'Regression of advanced fibrosis following virological response to anti-HCV therapy', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 29, pp. 85 - 85

Martinello M; Chow DH; Danta M; Matthews GV; Dore GJ, 2014, 'Safety and efficacy of telaprevir and boceprevir in the "real world": an Australian experience', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 29, pp. 85 - 86

Crane M; Avihingsanon A; Rajasuriar R; Velayudham P; Iser D; Solomon A; Sebolao B; Tran A; Spelman T; Matthews G; Cameron P; Tangkijvanich P; Dore GJ; Ruxrungtham K; Lewin SR, 2014, 'Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy', Journal of Infectious Diseases, 210, pp. 745 - 751, http://dx.doi.org/10.1093/infdis/jiu119

Achhra AC; Boyd MA; Law MG; Matthews GV; Kelleher AD; Cooper DA; Han A, 2014, 'Moving away from ritonavir, abacavir, tenofovir, and efavirenz (RATE) - Agents that concern prescribers and patients: A feasibility study and call for a trial', PLoS ONE, 9, pp. e99530, http://dx.doi.org/10.1371/journal.pone.0099530

Bradshaw D; Lamoury F; Catlett B; Mcallister J; Applegate T; Dore G; Matthews G; Danta M, 2014, 'Seminal HCV RNA level may mirror dynamics of plasma HCV RNA in HIV-infected men with acute HCV', HIV MEDICINE, 15, pp. 8 - 8

Bradshaw D; Applegate T; Dore G; Hellard M; Sasadeusz J; Matthews G; Danta M, 2014, 'The majority of acute HCV infection in HIV-positive men who have sex with men (HIV plus MSM) is transmitted permucosally in the context of HIV serosorting in Australia', HIV MEDICINE, 15, pp. 137 - 137

Avihingsanon A; Jitmitraparp S; Tangkijvanich P; Ramautarsing RA; Apornpong T; Jirajariyavej S; Putcharoen O; Treeprasertsuk S; Akkarathamrongsin S; Poovorawan Y; Matthews GV; Lange JM; Ruxrungtham K, 2014, 'Advanced liver fibrosis by transient elastography, Fibrosis 4, and alanine aminotransferase/platelet ratio index among Asian hepatitis C with and without human immunodeficiency virus infection: Role of vitamin D levels', Journal of Gastroenterology and Hepatology (Australia), 29, pp. 1706 - 1714, http://dx.doi.org/10.1111/jgh.12613

Giarda P; Avihingsanon A; Sasadeusz J; Audsley J; Marks P; Matthews G; Ruxrungtham K; Lewin SR; Crane M, 2014, 'CXCL-10, interleukin-12 and interleukin-21 are not immunological predictors of HBeAg seroconversion in HIV-1-HBV coinfection following HBV-active antiretroviral therapy', Antiviral Therapy, 19, pp. 429 - 433, http://dx.doi.org/10.3851/IMP2720

Avihingsanon A; Apornpong T; Ramautarsing RA; Ubolyam S; Tangkijvanich P; Ananworanich J; Lange JMA; Matthews G; Lewin SR; Ruxrungtham K, 2014, 'Decline in serum 25 hydroxyvitamin D levels in HIV-HBV-coinfected patients after long-term antiretroviral therapy', Antiviral Therapy, 19, pp. 41 - 49, http://dx.doi.org/10.3851/IMP2673

Holmes JA; Roberts SK; Ali RJ; Dore GJ; Sievert W; Mccaughan GW; Crawford DH; Cheng WS; Weltman MD; Bonanzinga S; Visvanathan K; Sundararajan V; Desmond PV; Bowden DS; Matthews GV; Thompson AJ, 2014, 'ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response', Hepatology, 59, pp. 2152 - 2160, http://dx.doi.org/10.1002/hep.27022

Feld JJ; Grebely J; Matthews GV; Applegate T; Hellard M; Sherker A; Cherepanov V; Petoumenos K; Yeung B; Kaldor JM; Lloyd AR; Dore GJ, 2013, 'Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection', PLoS ONE, 8, pp. e80003, http://dx.doi.org/10.1371/journal.pone.0080003

Grebely J; Matthews GV; Lloyd AR; Dore GJ, 2013, 'Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: Feasibility and future requirements', Clinical Infectious Diseases, 57, pp. 1014 - 1020, http://dx.doi.org/10.1093/cid/cit377

Holmes JA; Roberts SK; Sievert W; Dore GJ; Mccaughan M; Crawford DJ; Cheng W; Weltman M; Bonanzinga S; Visvanathan K; Desmond PV; Bowden DS; Matthews G; Thompson AJ, 2013, 'RBV pharmacokinetics explain the relationship between on-treatment anaemia and SVR, which is independent of ITPA genotype: analysis from the CHARIOT study', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 28, pp. 171 - 172

Taylor LE; Swan T; Matthews GV, 2013, 'Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy', Clinical Infectious Diseases, 57, http://dx.doi.org/10.1093/cid/cit326

Grebely J; Feld JJ; Applegate T; Matthews GV; Hellard M; Sherker A; Petoumenos K; Zang G; Shaw I; Yeung B; George J; Teutsch S; Kaldor JM; Cherepanov V; Bruneau J; Shoukry NH; Lloyd AR; Dore GJ, 2013, 'Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection', Hepatology, 57, pp. 2124 - 2134, http://dx.doi.org/10.1002/hep.26263

Suppiah V; Armstrong NJ; O'Connor KS; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Dore GJ; Irving WL; Powell E; Nattermann J; Mueller T; Riordan S; Stewart GJ; George J; Booth DR; Ahlenstiel G; Michalk M; Malik B; McClure P; Smith S; Sheridan D; Snape E; Fragomeli V; Norris R; How-Chow D; Jonsson JR; Barrie H; Stelzer-Braid S; Fletcher S; Applegate T; Grebely J; Matthews G; Bharadwaj M; Smedile A, 2013, 'CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection', Genes and Immunity, 14, pp. 286 - 290, http://dx.doi.org/10.1038/gene.2013.15

Matthews G; Seaberg E; Avihingsanon A; Bowden S; Dore GJ; Lewin SR; Sasadeusz JJ; Revill PA; Littlejohn M; Hoy J; Finlayson R; Ruxrungtham K; Saulynas M; Locarnini S; Thio C, 2013, 'Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus', Clinical Infectious Diseases, 56, pp. e87 - e94, http://dx.doi.org/10.1093/cid/cit002

Matthews GV; Ali RJ; Avihingsanon A; Amin J; Hammond RA; Bowden S; Lewin SR; Sasadeusz JJ; Littlejohn M; Locarnini SL; Ruxrungtham K; Dore GJ, 2013, 'Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals', PLoS One, 8, pp. e61297, http://dx.doi.org/10.1371/journal.pone.0061297

Hellard M; Grebely J; Yeung B; Dore G; Marks P; Shaw D; Byrne M; Matthews G, 2012, 'EFFECTIVENESS OF RESPONSE-GUIDED THERAPY IN RECENT HEPATITIS C INFECTION: THE AUSTRALIAN TRIAL IN ACUTE HEPATITIS C', DRUG AND ALCOHOL REVIEW, 31, pp. 33 - 33

Grebely J; Alavi M; Spelman T; Haber P; Day C; Matthews G; Van Beek I; Walsh N; Yeung B; Petoumenos K; Dolan K; Kaldor J; Dore G; Hellard M, 2012, 'IMPACT OF TREATMENT OF RECENTLY-ACQUIRED HEPATITIS C INFECTION ON INJECTING DRUG USE BEHAVIOURS', DRUG AND ALCOHOL REVIEW, 31, pp. 34 - 34

Holmes JA; Bonanzinga S; Roberts S; Sievert W; Dore G; Mccaughan G; Crawford DH; Cheng W; Weltman MD; Matthews G; Visvanathan K; Desmond P; Bowden DS; Thompson A, 2012, 'ITPA genotype strongly protects from ribavirin-induced haemolytic anaemia: analysis from the CHARIOT study', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 27, pp. 168 - 168

Cabuang LM; Shaw T; Littlejohn M; Colledge D; Sozzi V; Soppe S; Warner N; Thompson A; Preiss S; Lam N; Walsh R; Lewin SR; Thio CL; Matthews G; Locarnini SA; Revill PA, 2012, 'In vitro replication phenotype of a novel (-1G) hepatitis B virus variant associated with HIV co-infection', Journal of Medical Virology, 84, pp. 1166 - 1176, http://dx.doi.org/10.1002/jmv.23328

Botes LP; Pett SL; Carr AD; Marriott D; Cooper DA; Matthews G; Carbone S; Kumaradevan N; Mchugh L; Hillman R, 2012, 'Anal cytological abnormalities are poor predictors of high-grade intraepithelial neoplasia amongst HIV-positive men who have sex with men.', Sexual Health, 10, pp. 9 - 17, http://dx.doi.org/10.1071/SH11135

Avihingsanon A; Matthews GV; Lewin SR; Marks P; Sasadeusz JJ; Cooper DA; Bowden S; Locarnini SA; Dore GJ; Ruxrungtham K, 2012, 'Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand', AIDS Research and Therapy, 9, pp. Article number 6, http://dx.doi.org/10.1186/1742-6405-9-6

Grebely J; Matthews GV; Petoumenos K; Yeung B; Day C; Lloyd AR; Beek IV; Kaldor JM; Hellard M; Dore GJ; Haber PS; Alavi M; Van Beek I; Amin J; Dolan K; Rawlinson W; Flynn J; Marks P; Acraman B; Bloch M; Li H; Madden A; George J, 2012, 'Effect of pegylated interferon-a-2a treatment on mental health during recent hepatitis C virus infection', Journal of Gastroenterology and Hepatology, 27, pp. 957 - 965, http://dx.doi.org/10.1111/j.1440-1746.2011.07035.x

Flynn J; Dore GJ; Matthews G; Hellard M; Yeung B; Rawlinson W; White PA; Kaldor JM; Lloyd AR; Ffrench RA; Dolan K, 2012, 'Impaired hepatitis C virus (HCV)-specific interferon-responses in individuals with HIV who acquire HCV infection: Correlation with CD4 + T-cell counts', Journal of Infectious Diseases, 206, pp. 1568 - 1576, http://dx.doi.org/10.1093/infdis/jis544

Bradshaw D; Matthews G; Danta M, 2012, 'Sexually transmitted hepatitis C infection: The new epidemic in MSM?', Current Opinion in Infectious Diseases, 26, pp. 66 - 72, http://dx.doi.org/10.1097/QCO.0b013e32835c2120

Grebely J; Hellard M; Applegate TL; Petoumenos K; Yeung B; Feld J; Rawlinson WD; Lloyd AR; George J; Kaldor JM; Dore GJ; Matthews G; Dolan K, 2012, 'Virological responses during treatment for recent hepatitis C virus: Potential benefit for ribavirin use in HCV/HIV co-infection', AIDS, 26, pp. 1653 - 1661, http://dx.doi.org/10.1097/QAD.0b013e3283553719

Matthews GV; Dore GJ, 2011, 'HIV and Hepatitis C Co-Infection', , pp. 177 - 184, http://dx.doi.org/10.1002/9781444346343.ch22

Rockstroh J; Matthews G, 2011, 'Editorial introductions', Current Opinion in HIV and AIDS, 6, http://dx.doi.org/10.1097/COH.0b013e32834d219d

Matthews GV; Rockstroh J, 2011, 'HIV and hepatitis C coinfection', Current Opinion in HIV and AIDS, 6, pp. 449 - 450, http://dx.doi.org/10.1097/COH.0b013e32834bbf85

Matthews GV; Dore GJ, 2011, 'Optimal duration of treatment for acute hepatitis c in human immunodeficiency virus-positive individuals?', Hepatology, 53, pp. 1055 - 1056, http://dx.doi.org/10.1002/hep.24152

Danta M, 2011, 'Acute Hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference', AIDS, 25, pp. 399 - 409

Grebely J; Matthews G; Hellard M; Shaw D; van Beek I; Petoumenos K; Alavi M; Yeung B; Haber P; Lloyd AR; Kaldor JM; Dore GJ; Dolan K, 2011, 'Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users', Journal of Hepatology, 55, pp. 76 - 85, http://dx.doi.org/10.1016/j.jhep.2010.10.033

Audsley J; Seaberg E; Sasadcusz J; Matthews G; Avihingsanon A; Ruxrungtham K; Fairley K; Finlayson RJ; Hwang H; Littlejohn M; Locarnini S; Dore GJ; Thio C; Lewin S, 2011, 'Factors associated with elevated ALT in an international HIV/HBV Co-Infected cohort on long-term HAART', PLoS One, 6, pp. e26482, http://dx.doi.org/10.1371/journal.pone.0026482

Dore GJ; Matthews GV; Rockstroh J, 2011, 'Future of hepatitis C therapy: Development of direct-acting antivirals', Current opinion in HIV & AIDS, 6, pp. 508 - 513, http://dx.doi.org/10.1097/COH.0b013e32834b87f8

Smith KR; Suppiah V; O''Connor K; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Matthews G; Irving W; Powell E; Riordan S; Ahlensteil G; Stewart GJ; Bahlo M; Booth DR; George J, 2011, 'Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort', Genome Medicine, 3, pp. 57

Suppiah V; Gaudieri S; Armstrong N; O''connor K; Berg T; Weltman M; Abate M; Spengler U; Bassendine M; Dore G; Irving W; Powell E; Hellard M; Riordan S; Mathews G; Sheridan D; Natterman J; Smedile A; Muller T; Hammond E; Dunn D; Negro F; Bochud Y; Mallal S; Ahlenstiel G; Stewart G; George J; Booth D, 2011, 'IL28B, HLA-C and KIR variants additively and interactively predict response to therapy in chronic hepatitis C virus infection', PLOS Medicine, 8, pp. e1001092, http://dx.doi.org/10.1371/journal.pmed.1001092

Matthews G; Manzini P; Hu Z; Khabo P; Maja P; Matchaba G; Sangweni P; Metcalf K; Pool N; Orsega S; Emery S, 2011, 'Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa', AIDS, 25, pp. 1727 - 1735

Iser D; Avihingsanon A; Wisedopas N; Thompson AJ; Boyd A; Matthews G; Locarnini S; Slavin J; Desmond PV; Lewin S, 2011, 'Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression', AIDS, 25, pp. 197 - 205, http://dx.doi.org/10.1097/QAD.0b013e3283410ccb

Hillman R; Pett SL; Marriott D; Carr AD; Cooper DA; Matthews GV; Brew BJ; Milliken S; Botes LP, 2011, 'Participants' perspectives of high resolution anoscopy', Sexual Health, 8, pp. 255 - 256, http://search.informit.com.au/documentSummary;dn=026919938891985;res=IELHEA

Botes LP; Jin F; Bourne CP; Pett SL; Marriott D; Carr AD; Cooper DA; Matthews G; Brew BJ; Hillman R, 2011, 'Participants' perspectives of self-collected anal cytological swabs', Sexual Health, 8, pp. 257 - 258, http://search.informit.com.au/documentSummary;dn=026957204834502;res=IELHEA

Grebely J; Matthews GV; Petoumenos K; Dore GJ, 2010, 'Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection', Journal of Viral Hepatitis, 17, pp. 896, http://dx.doi.org/10.1111/j.1365-2893.2009.01256.x

Grebely J; Petoumenos K; Matthews G; Haber PS; Marks P; Lloyd AROLA; Kaldor JM; Dore GJ; Hellard M; Dolan K, 2010, 'Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study', Drug and Alcohol Dependence, 107, pp. 244 - 249, http://dx.doi.org/10.1016/j.drugalcdep.2009.09.015

van de Laar T; Matthews G; Prins MH; Danta M, 2010, 'Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection', AIDS, 24, pp. 1799 - 1812, http://dx.doi.org/10.1097/QAD.0b013e32833c11a5

Dore GJ; Hellard M; Matthews G; Grebely J; Haber PS; Petoumenos K; Yeung B; Marks P; Van Beek IA; McCaughan G; White PA; French R; Rawlinson WD; Lloyd AROLA; Kaldor JM; Dolan K, 2010, 'Effective treatment of injecting drug users with recently acquired hepatitis C virus infection', Gastroenterology, 138, pp. 123 - 135, http://dx.doi.org/10.1053/j.gastro.2009.09.019

Jin F; Prestage G; Matthews G; Zablotska I; Rawstorne PR; Kippax SC; Kaldor JM; Grulich AE, 2010, 'Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia', Sexually Transmitted Infections, 86, pp. 25 - 28, http://dx.doi.org/10.1136/sti.2009.038182

Haber P; Hellard M; Matthews GV; Grebely J; Petoumenos K; Yeung B; Marks P; Van Beek I; Kaldor J; Dore GJ, 2009, 'TREATMENT OF RECENT HEPATITIS C VIRUS INFECTION IN A PREDOMINANTLY INJECTION DRUG USER COHORT: THE ATAHC STUDY', DRUG AND ALCOHOL REVIEW, 28, pp. A27 - A27, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270916300083&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page